Abstract
The most significant potential risk of radioiodine therapy is bone marrow suppression. Therefore, in the treatment of distant metastases, lesion-based dosimetry is evaluated in conjunction with bone marrow dosimetry. It has been reported that an absorbed dose of at least 80 Gray (Gy) is required to effectively eradicate metastases. For this reason, in lesion-based dosimetry, the iodine-131 activity is calculated individually for each patient to deliver a minimum dose of 80 Gy to the tumor.
Keywords: Lesion dosimetry, radioiodine therapy, tumor dosimetry in I-131 treatment
References
Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol. 2007;8:148-156.
Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid. 2002;12:121-134.
Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab. 2007;92:28-38.
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer; Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214. Erratum in: Thyroid. 2010;20:942. Hauger, Bryan R [corrected to Haugen, Bryan R]. Erratum in: Thyroid. 2010;20:674-675.
Lee JJ, Chung JK, Kim SE, et al. Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma. Ann Nucl Med. 2008;22:727-734.
Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962;87:171-182.
Benua RS, Leeper RD. A method and rationale for treating thyroid carcinoma with the largest safe dose of I-131. In: Meideros-Neto GA, Gaitan E. (eds.). Frontiers of Thyroidology. New York, NY: Plenum, 1986.
Willegaignon J, Sapienza MT, Buchpiguel CA. Comparison of different dosimetric methods for red marrow absorbed dose calculation in thyroid cancer therapy. Radiat Prot Dosimetry. 2012;149:138-146.
Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941-1959.
Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309:937-941.
Siegel JA, Thomas SR, Stubbs JB, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40:37S-61S.
Brown S, Bailey DL, Willowson K, Baldock C. Investigation of the relationship between linear attenuation coefficients and CT Hounsfield units using radionuclides for SPECT. Appl Radiat Isot. 2008;66:1206-1212.
